Categories Earnings, Health Care

Exact Sciences Corp. (EXAS): Q4 2019 Earnings Snapshot

— Exact Sciences Corp. (NASDAQ: EXAS) reported Q4 2019 earnings of $0.54 per share, vs. a loss of $0.35 expected.

— Total revenues were $295.6 million, vs. $283 million expected.

— Screening revenues increased 60% to $229.4 million.

— Cologuard test volume rose 63% to 477,000.

— Average Cologuard recognized revenue per test was $481.

— Average Cologuard cost per test was $123.

— Precision Oncology proforma revenue increased 14% to $119.1 million.

— FY2020 consolidated revenue is expected to be $1.61-1.64 billion.

— FY2020 Screening revenue is expected to be $1.125-1.15 billion.

— FY2020 Precision Oncology revenue is expected to be $485-495 million.

— EXAS shares gained 1.2% immediately following the announcement.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

LUV Earnings: Key numbers from Southwest Airlines Q1 2021 financial results

Southwest Airlines Co. (NYSE: LUV) today reported its first quarter financial results for the period ended March 31, 2021. First quarter GAAP net income was $116 million, or $0.19 per

Infographic: American Airlines (AAL) posts Q1 2021 earnings today

Aviation company American Airlines Group Inc. (NASDAQ: AAL) reported its first-quarter 2021 earnings before regular market hours. The operating revenue for the first quarter of 2021 was down by 39% at

Infographic: How Biogen (BIIB) performed in Q1 2021

Biogen Inc. (NASDAQ: BIIB) reported first quarter 2021 earnings results today. Total revenues decreased 24% year-over-year to $2.6 billion. On a constant currency basis, revenues fell 25%. Net income attributable

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top